Last reviewed · How we verify
Ad4-H5-Vtn
At a glance
| Generic name | Ad4-H5-Vtn |
|---|---|
| Also known as | Adenovirus Serotype 4-vectored H5N1 Influenza Vaccine |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1 (PHASE1)
- Experimental AD4-H5-VTN Vaccine in Healthy Volunteers (PHASE1)
- Intranasal AD4-H5-VTN as an Adenovirus Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad4-H5-Vtn CI brief — competitive landscape report
- Ad4-H5-Vtn updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI